Abstract |
We evaluated the antinociceptive effect of Gosha-jinki-gan, a Kampo medicine including processed Aconiti tuber, and its mechanism in streptozotocin-induced diabetic mice. Gosha-jinki-gan (0.1-1.0 g/kg, p.o.) showed a more potent antinociceptive effect in diabetic mice than in non-diabetic mice. The antinociceptive effect of Gosha-jinki-gan (0.3 g/kg, p.o.) in diabetic mice was inhibited by administration of either anti- dynorphin antiserum (5 microg, i.t.) or nor-binaltorphimine (10 mg/kg, s.c.), a kappa- opioid antagonist. The antinociceptive activity of Gosha-jinki-gan (0.3, 1.0 g/kg, p.o.) was decreased by excluding processed Aconiti tuber. Furthermore, the antinociceptive effect of processed Aconiti tuber (0.03, 0.1 g/kg, p.o.) was also shown to be enhanced in diabetic mice. These results suggest that the increased antinociceptive effect of Gosha-jinki-gan in diabetic mice is partly derived from the action of processed Aconiti tuber and that it is based on stimulation of spinal kappa-opioid receptors via dynorphin release. Gosha-jinki-gan was considered useful for treating painful diabetic neuropathy.
|
Authors | Y Suzuki, K Goto, A Ishige, Y Komatsu, J Kamei |
Journal | Japanese journal of pharmacology
(Jpn J Pharmacol)
Vol. 79
Issue 2
Pg. 169-75
(Feb 1999)
ISSN: 0021-5198 [Print] Japan |
PMID | 10202852
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Analgesics
- Drugs, Chinese Herbal
- Immune Sera
- gosha-jinki-gan
- Dynorphins
|
Topics |
- Analgesics
(pharmacology, therapeutic use)
- Animals
- Diabetes Mellitus, Experimental
(complications)
- Diabetic Neuropathies
(drug therapy)
- Drugs, Chinese Herbal
(pharmacology, therapeutic use)
- Dynorphins
(antagonists & inhibitors, immunology)
- Immune Sera
(pharmacology)
- Male
- Mice
- Pain Measurement
- Time Factors
|